{"owner": "ArrayExpress Uploader", "pop_total": 0, "id": 3332, "factors": [{"GSM421899": {"clinical treatment": "none", "phenotype": "intravenous immunoglobulin responsive"}}, {"GSM421900": {"clinical treatment": "intravenous immunoglobulin ", "phenotype": "intravenous immunoglobulin responsive"}}, {"GSM421899": {"clinical treatment": "none", "phenotype": "intravenous immunoglobulin responsive"}}, {"GSM421900": {"clinical treatment": "intravenous immunoglobulin ", "phenotype": "intravenous immunoglobulin responsive"}}, {"GSM421899": {"clinical treatment": "none", "phenotype": "intravenous immunoglobulin responsive"}}, {"GSM421900": {"clinical treatment": "intravenous immunoglobulin ", "phenotype": "intravenous immunoglobulin responsive"}}, {"GSM421899": {"clinical treatment": "none", "phenotype": "intravenous immunoglobulin responsive"}}, {"GSM421900": {"clinical treatment": "intravenous immunoglobulin ", "phenotype": "intravenous immunoglobulin responsive"}}, {"GSM421899": {"clinical treatment": "none", "phenotype": "intravenous immunoglobulin responsive"}}, {"GSM421900": {"clinical treatment": "intravenous immunoglobulin ", "phenotype": "intravenous immunoglobulin responsive"}}, {"GSM421899": {"clinical treatment": "none", "phenotype": "intravenous immunoglobulin responsive"}}, {"GSM421900": {"clinical treatment": "intravenous immunoglobulin ", "phenotype": "intravenous immunoglobulin responsive"}}, {"GSM4219": {"clinical treatment": "none", "phenotype": "intravenous immunoglobulin resistant"}}, {"GSM421912": {"clinical treatment": "intravenous immunoglobulin ", "phenotype": "intravenous immunoglobulin resistant"}}, {"GSM4219": {"clinical treatment": "none", "phenotype": "intravenous immunoglobulin resistant"}}, {"GSM421912": {"clinical treatment": "intravenous immunoglobulin ", "phenotype": "intravenous immunoglobulin resistant"}}, {"GSM4219": {"clinical treatment": "none", "phenotype": "intravenous immunoglobulin resistant"}}, {"GSM421912": {"clinical treatment": "intravenous immunoglobulin ", "phenotype": "intravenous immunoglobulin resistant"}}, {"GSM4219": {"clinical treatment": "none", "phenotype": "intravenous immunoglobulin resistant"}}, {"GSM421912": {"clinical treatment": "intravenous immunoglobulin ", "phenotype": "intravenous immunoglobulin resistant"}}, {"GSM4219": {"clinical treatment": "none", "phenotype": "intravenous immunoglobulin resistant"}}, {"GSM421912": {"clinical treatment": "intravenous immunoglobulin ", "phenotype": "intravenous immunoglobulin resistant"}}, {"GSM4219": {"clinical treatment": "none", "phenotype": "intravenous immunoglobulin resistant"}}, {"GSM421912": {"clinical treatment": "intravenous immunoglobulin ", "phenotype": "intravenous immunoglobulin resistant"}}, {"GSM4219": {"clinical treatment": "none", "phenotype": "intravenous immunoglobulin resistant"}}, {"GSM421924": {"clinical treatment": "intravenous immunoglobulin and methylprednisolone", "phenotype": "intravenous immunoglobulin resistant"}}, {"GSM4219": {"clinical treatment": "none", "phenotype": "intravenous immunoglobulin resistant"}}, {"GSM421924": {"clinical treatment": "intravenous immunoglobulin and methylprednisolone", "phenotype": "intravenous immunoglobulin resistant"}}, {"GSM4219": {"clinical treatment": "none", "phenotype": "intravenous immunoglobulin resistant"}}, {"GSM421924": {"clinical treatment": "intravenous immunoglobulin and methylprednisolone", "phenotype": "intravenous immunoglobulin resistant"}}, {"GSM4219": {"clinical treatment": "none", "phenotype": "intravenous immunoglobulin resistant"}}, {"GSM421924": {"clinical treatment": "intravenous immunoglobulin and methylprednisolone", "phenotype": "intravenous immunoglobulin resistant"}}, {"GSM4219": {"clinical treatment": "none", "phenotype": "intravenous immunoglobulin resistant"}}, {"GSM421924": {"clinical treatment": "intravenous immunoglobulin and methylprednisolone", "phenotype": "intravenous immunoglobulin resistant"}}], "ownerprofile_id": "arrayexpress_sid", "platform": 4, "summary_wrapped": "Clinical score and transcript abundance patterns identify Kawasaki disease patients who may benefit from addition of methylprednisolone....", "pubmed_id": 19680167, "geo_gse_id": "E-GEOD-16797", "owner_profile": "/profile/8773/arrayexpressuploader", "factor_count": 2, "sample_count": 34, "tags": ["artery", "cell", "cell adhesion molecule", "coronary artery", "cytokine", "disease", "group b", "immunoglobulin", "kawasaki disease", "polycythemia", "protein"], "lastmodified": "Dec.12, 2014", "is_default": false, "geo_gds_id": "", "slug": "transcription-profiling-by-array-of-human-periph-8", "geo_id_plat": "E-GEOD-16797_A-AFFY-44", "name": "Transcription profiling by array of human peripheral blood samples from Kawasaki disease patients after treatment with intravenous immunoglobulin and methylprednisolone", "created": "Sep.12, 2014", "summary": "Clinical score and transcript abundance patterns identify Kawasaki disease patients who may benefit from addition of methylprednisolone. Intravenous immunoglobulin (IVIG) treatment-resistant patients are high risk of developing coronary artery lesions (CALs) with Kawasaki disease (KD). The IVIG-responsive (Group A; n = 6) and -resistant patients (Group B) were predicted before starting the initial treatment using the Egami scoring system, and randomly allocated a single-IVIG treatment group (Group B1; n = 6) or a IVIG-plus-methylprednisolone (IVMP) combined therapy group (Group B2; n = 5). We investigated transcript abundance in the leukocytes of those patients using microarray analysis. Results: five patients in Group A and 1 patient in Group B1 responded to initial IVIG treatment. All Group B2 patients responded to IVIP-plus-IVMP combined therapy. Prior to performing these treatments, those transcripts related to IVIG-resistance and to the development of CALs, such as IL1R, IL18R, oncostatin M, suppressor of cytokine signaling-3, S100A12 protein, carcinoembryonic antigen-related cell adhesion molecule-1, matrix metallopeptidase-9 and polycythemia rubra vera-1 were more abundant in Group B patients in comparison to Group A patients. Moreover, those transcripts in Group B2 patients were more profoundly and broadly suppressed than Group B1 patients after treatment.                                                        Conclusion: this study elucidated the molecular mechanism of the effectiveness of IVIG-plus-IVMP combined therapy. 34 samples of pre- and post-treatment in three groups consisting of predicted as  IVIG-responsive patients,  given single-IVIG treatment patients and IVIG-plus-IVMP combined therapy group in predicted as IVIG-resistant patients. Samples were analyzed without replicates.", "source": "http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-16797", "species": "human", "sample_source": "http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-16797/samples/"}